博雅生物(300294.SZ):公司股票交易可能被實施其他風險警示
格隆匯3月4日丨博雅生物(300294.SZ)公佈,公司於2021年3月3日披露了《關於收到江西證監局對公司及相關責任人、控股股東採取責令改正措施決定的公吿》(《責令改正公吿》),至目前,博雅生物製藥(廣東)有限公司(“博雅(廣東)”)未向公司歸還採購原料血漿款項約7.23億元及同期銀行活期存款利息,且博雅(廣東)未向公司供應原料血漿,上述事項構成關聯方佔用上市公司資金。
根據《深圳證券交易所創業板股票上市規則》第9.4條“上市公司出現下列情形之一的,本所對其股票交易實施其他風險警示:……(五)公司向控股股東或者其關聯人提供資金或者違反規定程序對外提供擔保且情形嚴重的;……”,第9.5條“……本規則第9.4條第五項所述‘向控股股東或者其關聯人提供資金或者違反規定程序對外提供擔保且情形嚴重’,是指上市公司存在下列情形之一且無可行的解決方案或者雖提出解決方案但預計無法在一個月內解決的……”。
針對關聯方佔用上市公司資金事項,公司及相關方一直在尋求解決方案。
2021年3月4日,深圳市高特佳投資集團有限公司股東蘇州德萊電器有限公司的關聯方蘇州愛普電器有限公司向公司承諾,代博雅(廣東)履行向公司返還剩餘的採購原料血漿款項約7.23億元及同期銀行活期存款利息的義務。公司及相關方力爭在一個月內解決關聯方佔用上市公司資金事項,如屆時未得到解決,公司股票交易可能被實施其他風險警示(股票簡稱前冠以“ST”字樣)。公司將根據上述事項的進展情況及時披露信息。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.